Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone

Frontiers in Pharmacology

Volumn 7, Issue OCT, 2016, Pages

  Lolli, Cristian ^a   Caffo, Orazio ^b   Scarpi, Emanuela ^a   Aieta, Michele ^c   Conteduca, Vincenza ^a   Maines, Francesca ^b   Bianchi, Emanuela ^d   Massari, Francesco ^e   Veccia, Antonello ^b   Chiuri, Vincenzo E ^f   Facchini, Gaetano ^g   De Giorgi, Ugo ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

^c Laboratory of Clinical Research and Molecular Diagnostics   (Italy)

^d Infermi Hospital   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f VITO FAZZI HOSPITAL   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Abiraterone; CRPC; Prognostic factor; Prostate cancer; PSA; Systemic immune inflammation index

Indexed keywords

ABIRATERONE; DOCETAXEL; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; FUNCTIONAL STATUS ASSESSMENT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; PROGNOSTIC ASSESSMENT; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SYSTEMIC IMMUNE INFLAMMATION INDEX; VISCERAL METASTASIS;

EID: 84995404248     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00376     Document Type: Article

References (34)

1. Attard, G., Parker, C., Eeles, R. A., Schröder, F., Tomlins, S. A., Tannock, I., et al. (2016). Prostate cancer. Lancet 387, 70-82. doi: 10.1016/S0140-6736(14)61947-4
2. Azad, A. A., Volik, S. V., Wyatt, A. W., Haegert, A., Le Bihan, S., Bell, R. H., et al. (2015). Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin. Cancer Res. 21, 2315-2324. doi: 10.1158/1078-0432.CCR-14-2666
3. Bishop, J. L., Sio, A., Angeles, A., Roberts, M. E., Azad, A. A., Chi, K. N., et al. (2015). PD-L1 is highly expressed in enzalutamide resistant prostate cancer. Oncotarget 6, 234-242. doi: 10.18632/oncotarget.2703
4. Brennen, W. N., Denmeade, S. R., and Isaacs, J. T. (2013). Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr. Relat. Cancer 20, R269-R290.
5. Burgio, S. L., Conteduca, V., Menna, C., Carretta, E., Rossi, L., Bianchi, E., et al. (2014). Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Endocr. Relat. Cancer 21, 487-493. doi: 10.1530/ERC-14-0071
6. Cannon, N. A., Meyer, J., Iyengar, P., Ahn, C., Westover, K. D., Choy, H., et al. (2015). Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J. Thorac. Oncol. 10, 280-285. doi: 10.1097/JTO.0000000000000399
7. Conteduca, V., Aieta, M., Amadori, D., and De Giorgi, U. (2014). Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies. Crit. Rev. Oncol. Hematol. 92, 11-24. doi: 10.1016/j.critrevonc.2014.05.008
8. Conteduca, V., Caffo, O., Fratino, L., Lo Re, G., Basso, U., D'Angelo, A., et al. (2015). Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. Future Oncol. 11, 2881-2891. doi: 10.2217/fon.15.158
9. Conteduca, V., Crabb, S. J., Jones, R. J., Caffo, O., Elliott, T., Scarpi, E., et al. (2016). Persistent neutrophil to lymphocyte ratio during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer. PLoS ONE 11:e0158952. doi: 10.1371/journal.pone.0158952
10. de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., et al. (2011). Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005. doi: 10.1056/NEJMoa1014618
11. de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J. P., Kocak, I., et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147-1154. doi: 10.1016/j.eururo.2011.01.021
12. de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., et al. (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14, 6302-6309. doi: 10.1158/1078-0432.CCR-08-0872
13. De Giorgi, U., Mego, M., Scarpi, E., Giordano, A., Giuliano, M., Valero, V., et al. (2016). Correlation of circulating tumor cells (CTCs) with peripheral blood leukocytes to predict outcome in metastatic breast cancer (MBC). J. Clin. Oncol 34(Suppl.), 11532.
14. De Giorgi, U., Mego, M., Scarpi, E., Giuliano, M., Giordano, A., Reuben, J. M., et al. (2012). Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin. Breast Cancer 12, 264-269. doi: 10.1016/j.clbc.2012.04.004
15. De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., et al. (2007). Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 7, 256-269. doi: 10.1038/nrc2090
16. Graff, J. N., Alumkal, J. J., Drake, C. G., Thomas, G. V., Redmond, W. L., Farhad, M., et al. (2016). Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 12. doi: 10.18632/oncotarget.10547 [Epub ahead of print].
17. Hu, B., Yang, X. R., Xu, Y., Sun, Y. F., Sun, C., Guo, W., et al. (2014). Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin. Cancer Res. 20, 6212-6222. doi: 10.1158/1078-0432.CCR-14-0442
18. Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422. doi: 10.1056/NEJMoa1001294
19. Leibowitz-Amit, R., Templeton, A. J., Omlin, A., Pezaro, C., Atenafu, E. G., Keizman, D., et al. (2014). Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann. Oncol. 25, 657-662. doi: 10.1093/annonc/mdt581
20. Lolli, C., Basso, U., Derosa, L., Scarpi, E., Sava, T., Santoni, M., et al. (2016). Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget 9. doi: 10.18632/oncotarget.10515 [Epub ahead of print].
21. Lorente, D., Mateo, J., Templeton, A. J., Zafeiriou, Z., Bianchini, D., Ferraldeschi, R., et al. (2015). Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann. Oncol. 26, 750-755. doi: 10.1093/annonc/mdu587
22. Lorente, D., Olmos, D., Mateo, J., Bianchini, D., Seed, G., Fleisher, M., et al. (2016). Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer. Eur. Urol. 8. doi: 10.1016/j.eururo.2016.05.023 [Epub ahead of print].
23. Mego, M., Gao, H., Cohen, E. N., Anfossi, S., Giordano, A., Sanda, T., et al. (2016). Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer. J. Cancer 7, 1095-1104. doi: 10.7150/jca.13098
24. Nuhn, P., Vaghasia, A. M., Goyal, J., Zhou, X. C., Carducci, M. A., Eisenberger, M. A., et al. (2014). Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int. 114, E11-E17. doi: 10.1111/bju.12531
25. Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., et al. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213-223. doi: 10.1056/NEJMoa1213755
26. Passardi, A., Scarpi, E., Cavanna, L., Dall'Agata, M., Tassinari, D., Leo, S., et al. (2016). Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget 7, 33210-33219. doi: 10.18632/oncotarget.8901
27. Rescigno, P., Lorente, D., Bianchini, D., Ferraldeschi, R., Kolinsky, M. P., Sideris, S., et al. (2016). Prostate-specific antigen decline after 4 weeks of treatment with abiraterone acetate and overall survival in patients with metastatic castration-resistant prostate cancer. Eur. Urol. 7. doi: 10.1016/j.eururo.2016.02.055 [Epub ahead of print].
28. Rossi, L., Santoni, M., Crabb, S. J., Scarpi, E., Burattini, L., Chau, C., et al. (2015). High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann. Surg. Oncol. 22, 1377-1384. doi: 10.1245/s10434-014-4097-4
29. Salvi, S., Casadio, V., Conteduca, V., Burgio, S. L., Menna, C., Bianchi, E., et al. (2015). Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. Br. J. Cancer 112, 1717-1724. doi: 10.1038/bjc.2015.128
30. Saylor, P. J., Kozak, K. R., Smith, M. R., Ancukiewicz, M. A., Efstathiou, J. A., Zietman, A. L., et al. (2012). Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist 17, 212-219. doi: 10.1634/theoncologist.2011-0321
31. Scher, H. I., Fizazi, K., Saad, F., Taplin, M. E., Sternberg, C. N., Miller, K., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197. doi: 10.1056/NEJMoa1207506
32. Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., et al. (2008). Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148-1159. doi: 10.1200/JCO.2007.12.4487
33. Siegel, R. L., Miller, K. D., and Jemal, A. (2016). Cancer statistics, 2016. CA Cancer J. Clin. 66, 7-30. doi: 10.3322/caac.21349
34. Templeton, A. J., McNamara, M. G., Seruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A., et al. (2014). Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl. Cancer Inst. 106, 1-11. doi: 10.1093/jnci/dju124